Neurobiology of Aging
Volume 28, Issue 8 , Pages 1139-1147 , August 2007

Aβ42 neurotoxicity in primary co-cultures: Effect of apoE isoform and Aβ conformation

  • Arlene M. Manelli

      Affiliations

    • Department of Medicine, Division of Geriatrics, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, United States
    • Permanent address: Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6123, United States.
    • ,
  • Lindsey C. Bulfinch

      Affiliations

    • Department of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., CME 578, M/C 512, Chicago, IL 60612, United States
    • ,
  • Patrick M. Sullivan

      Affiliations

    • Department of Medicine, Division of Neurology and Bryan ADRC, Duke University, Durham, NC 27710, United States
    • ,
  • Mary Jo LaDu

      Affiliations

    • Department of Medicine, Division of Geriatrics, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 312 355 4795; fax: +1 312 355 0386.

Received 21 April 2006 ,Revised 18 May 2006 ,Accepted 19 May 2006.

References 

  1. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42(9):1681–1688
  2. Banker G, Goslin K . Culturing nerve cells. vol. xiii. Cambridge, MA: MIT Press; 1991;p. 453
  3. Bowman BH, Jansen L, Yang F, Adrian GS, Zhao M, Atherton SS, et al. Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. Proc Natl Acad Sci USA. 1995;92:12115–12119
  4. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501–1513
  5. Butterfield DA. Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity, implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res. 2002;36(12):1307–1313
  6. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, et al. Expression of human apolipoprotein E3 or E4 in the brains of ApoE−/− mice, isoform-specific effects on neurodegeneration. J Neurosci. 1999;19(12):4867–4880
  7. Corder EH, Saunder SM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180–184
  8. Cummings BJ, Cotman CW. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995;346(8989):1524–1528
  9. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277(35):32046–32053
  10. DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, et al. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int. 2001;39(5–6):415–425
  11. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W, et al. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol. 1991;65:4759–4768
  12. Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2005;102(4):1211–1216
  13. Drouet B, Fifre A, Pincon-Raymond M, Vandekerckhove J, Rosseneu M, Gueant JL, et al. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 2001;76(1):117–127
  14. Forloni G, Lucca E, Angeretti N, Della Torre P, Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J Neurochem. 1997;69(5):2048–2054
  15. Fryer JD, Demattos RB, McCormick LM, O’Dell MA, Spinner ML, Bales KR, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280(27):25754–25759
  16. Fujita SC, Sakuta K, Tsuchiya R, Hamanaka H. Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain. Neurosci Res. 1999;35(2):123–133
  17. Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS. Neuropathology and apolipoprotein E profile of aged chimpanzees, implications for Alzheimer disease. Proc Natl Acad Sci USA. 1994;91(20):9382–9386
  18. Golde TE. Alzheimer disease therapy, can the amyloid cascade be halted?. J Clin Invest. 2003;111(1):11–18
  19. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 2001;21(3):812–822
  20. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease, progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356
  21. Harris FM, Tesseur I, Brecht WJ, Xu Q, Mullendorff K, Chang S, et al. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem. 2004;279(5):3862–3868
  22. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem. 2005;93(1):145–155
  23. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96(6):3228–3233
  24. Hu J, Castets F, Guevara JL, Van Eldik LJ. S100β stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem. 1996;271:2543–2547
  25. Hu J, LaDu MJ, Van Eldik LJ. Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. J Neurochem. 1998;71(4):1626–1634
  26. Hu J, Van Eldik LJ. S100 beta induces apoptotic cell death in cultured astrocytes via a nitric oxide-dependent pathway. Biochim Biophys Acta. 1996;1313(3):239–245
  27. Huber G, Marz W, Martin JR, Malherbe P, Richards JG, Sueoka N, et al. Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P; C112R). Neuroscience. 2000;101(1):211–218
  28. Innerarity T, Hui D, Bersot T, Mahley RW. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. Adv Exp Med Biol. 1986;201:273–288
  29. Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978;17(8):1440–1447
  30. Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem. 2004;90(5):1132–1143
  31. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053–7059
  32. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci. 1998;18(1):195–204
  33. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers, the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001;24(4):219–224
  34. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors, macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 1994;63:601–637
  35. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem. 1994;269:23404–23406
  36. LaDu MJ, Gilligan SM, Lukens SR, Cabana VG, Reardon CA, Van Eldik LJ, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070–2081
  37. LaDu MJ, Lukens JR, Reardon CA, Getz GS. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 1997;49(1):9–18
  38. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem. 1995;270:9030–9042
  39. LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, et al. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int. 2001;39(5–6):427–434
  40. LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, et al. Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J Biol Chem. 2000;275(43):33974–33980
  41. Ladu MJ, Stine WB, Narita M, Getz GS, Reardon CA, Bu G. Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein. Biochemistry. 2006;45(2):381–390
  42. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer's Abeta(1–42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002;924(1):90–97
  43. Levison SW, McCarthy KD. Characterization and partial purification of AIM, a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors. J Neurochem. 1991;57(3):782–794
  44. Liu Y, Schubert D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem. 1997;69(6):2285–2293
  45. Ma J, Brewer HB, Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol Aging. 1996;17(5):773–780
  46. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ. ApoE and Abeta1–42 interactions, effects of isoform and conformation on structure and function. J Mol Neurosci. 2004;23(3):235–246
  47. Manelli AM, Sullivan PM, LaDu MJ. Amyloid-beta1–42 induced neurotoxicity in cells co-cultured with glia from apoE targeted replacement mice. Program No. 407.18; 2003.
  48. Manelli AM, Sullivan PM, LaDu MJ. Effect of Abeta structure and human apoE isoform on primary co-cultures of neurons and glia. Program No. 442.2; 2004.
  49. Mazur-Kolecka B, Frackowiak J, Carroll RT, Wisniewski HM. Accumulation of Alzheimer amyloid-beta peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid. J Neuropathol Exp Neurol. 1997;56(3):263–272
  50. Mazur-Kolecka B, Frackowiak J, Krzeslowska J, Ramakrishna N, Haske T, Emmerling MR, et al. Apolipoprotein E alters metabolism of AbetaPP in cells engaged in beta-amyloidosis. J Neuropathol Exp Neurol. 1999;58(3):288–295
  51. Mazur-Kolecka B, Frackowiak J, Le Vine H, Haske T, Evans L, Sukontasup T, et al. TGFbeta1 enhances formation of cellular Abeta/apoE deposits in vascular myocytes. Neurobiol Aging. 2003;24(2):355–364
  52. Mazur-Kolecka B, Frackowiak J, Wisniewski HM. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 1995;698(1–2):217–222
  53. Mazur-Kolecka B, Kowal D, Sukontasup T, Dickson D, Frackowiak J. The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA). Brain Res. 2003;983(1–2):48–57
  54. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61
  55. Mosmann T. Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65(1–2):55–63
  56. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice, synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050–4058
  57. Mufson EJ, Benzing WC, Cole GM, Wang H, Emerich DF, Sladek JR, et al. Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex, colocalization with amyloid plaques. Neurobiol Aging. 1994;15(5):621–627
  58. Nakai M, Kawamata T, Maeda K, Tanaka C. Expression of apoE mRNA in rat microglia. Neurosci Lett. 1996;211:41–44
  59. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759–767
  60. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA. 1992;89:4471–4475
  61. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917:148–161
  62. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343–353
  63. Poirier J, Hess M, May PC, Finch CE. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res. 1991;11:97–106
  64. Qiu Z, Crutcher KA, Hyman BT, Rebeck GW. ApoE isoforms affect neuronal N-methyl-d-aspartate calcium responses and toxicity via receptor-mediated processes. Neuroscience. 2003;122(2):291–303
  65. Qiu Z, Hyman BT, Rebeck GW. Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J Biol Chem. 2004;279(33):34948–34956
  66. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice, increased susceptibility of females. Proc Natl Acad Sci USA. 1998;95(18):10914–10919
  67. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, et al. Apolipoprotein E and cognitive performance. Nature. 2000;404(6776):352–354
  68. Ramaswamy G, Xu Q, Huang Y, Weisgraber KH. Effect of domain interaction on apolipoprotein E levels in mouse brain. J Neurosci. 2005;25(46):10658–10663
  69. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease, allelic variation and receptor interactions. Neuron. 1993;11(4):575–580
  70. Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, et al. Characterization of the apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;
  71. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, et al. Apolipoprotein E serum concentration and polymorphism in six European countries, the ApoEurope Project. Atherosclerosis. 2000;152(2):475–488
  72. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789–791
  73. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet. 2002;6:6
  74. Smith JD, Sikes J, Levin JA. Human apolipoprotein E allele-specific brain expressing transgenic mice. Neurobiol Aging. 1998;19(5):407–413
  75. Stine WB, Dahlgren KN, Krafft GK, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612–11622
  76. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 1997;143:313–318
  77. Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids. 2005;137(1–2):52–61
  78. Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124(4):725–733
  79. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972–17980
  80. Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, et al. GFAP-apoE transgenic mice: astrocyte specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998;18:3261–3272
  81. Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, et al. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol. 2000;157(5):1495–1510
  82. Teter B. ApoE-dependent plasticity in Alzheimer's disease. J Mol Neurosci. 2004;23(3):167–180
  83. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β-peptide. Biochem J. 2000;348:359–365
  84. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Blaine Stine W, et al. ApoE isoform-specific effects on LTP, blockade by oligomeric amyloid-beta1–42. Neurobiol Dis. 2005;18(1):75–82
  85. Urmoneit B, Prikulis I, Wihl G, D’Urso D, Frank R, Heeren J, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway, implications for cerebral amyloid angiopathy. Lab Invest. 1997;77(2):157–166
  86. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, LaDu MJ. Differential effects of oligomeric and fibrillar amyloid-beta1–42 on astrocyte-mediated inflammation. Neurobiol Dis. 2005;18(3):459–465
  87. Whitson JS, Mims MP, Strittmatter WJ, Yamaki T, Morrisett JD, Appel SH. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun. 1994;199(1):163–170
  88. Xu P-T, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu H-L, Popko B, et al. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice, human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis. 1996;3:229–245
  89. Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, et al. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem. 2004;90(4):1011–1018
  90. Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, et al. Apolipoprotein (apo) E4 enhances amyloid {beta} peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA. 2005;

PII: S0197-4580(06)00185-0

doi: 10.1016/j.neurobiolaging.2006.05.024

Neurobiology of Aging
Volume 28, Issue 8 , Pages 1139-1147 , August 2007

Article Tools

* Image Usage & Resolution